{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:05:38Z","timestamp":1792638338080,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Resmetirom can slow fibrosis progression and improve resolution of metabolic dysfunction\u2013associated steatohepatitis (MASH). As the first Food and Drug Administration\u2013approved pharmacologic treatment for MASH and fibrosis stages F2 and F3, resmetirom is very expensive, potentially creating a financial barrier to patient access.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the cost-effectiveness of resmetirom vs standard of care (SoC) over a lifetime and to determine a price threshold at which resmetirom would be cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation used an agent-based state-transition microsimulation model with a yearly cycle and 14 distinct histologically defined health states: metabolic dysfunction\u2013associated steatotic liver disease (MALSD) or F0, MASH, fibrosis stages F1 to F3 with or without MASH, cirrhosis, decompensated cirrhosis, liver cancer, liver transplant, and liver-related and other-cause death. The simulated cohort included US adults who entered the model with MASH and fibrosis stage F2 or F3. The study was conducted from March to December 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Resmetirom vs SoC.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Costs (in 2023 US dollars), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) (calculated as incremental costs divided by incremental QALYs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A cohort of 200\u202f000 patients (mean [SD] age, 57.1 [10.5] years; 89\u202f000 [44.5%] male; 132\u202f600 [66.2%] with MASH-F3) was simulated. Compared with SoC, resmetirom was associated with a gain of 0.26 QALYs\/patient. Lifetime drug cost was $54\u202f754, and treatment saved $18\u202f499 in MASLD-related medical costs for a total incremental cost of $36\u202f255 per patient. The ICER was $140\u202f134\/QALY. At willingness-to-pay (WTP) thresholds of $50\u202f000\/QALY, $100\u202f000\/QALY, and $150\u202f000\/QALY, the maximal annual prices of resmetirom were $10\u202f914, $15\u202f406, and $19\u202f879, respectively. The lower the discontinuation rate, the greater the cost-effectiveness and medical cost savings, but the higher the total treatment costs. Without discontinuation, the ICER would be $318\u202f740\/QALY, supporting a price between $5645 and $10\u202f619 per year at WTP thresholds of $50\u202f000\/QALY and $150\u202f000\/QALY, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation, resmetirom was not cost-effective at a $100\u202f000\/QALY WTP threshold. The conclusion was sensitive to model assumptions, especially the discontinuation rate. More data on the long-term effectiveness of resmetirom on MASLD progression and non-MASLD complications would be necessary to accurately determine the economic value of resmetirom.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.17122","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:30:31Z","timestamp":1751023831000},"page":"e2517122","source":"Crossref","is-referenced-by-count":21,"title":["Value-Based Pricing of Resmetirom for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease"],"prefix":"10.1001","volume":"8","author":[{"given":"Phuc","family":"Le","sequence":"first","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Dasarathy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor"},{"name":"University of Michigan School of Medicine, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajide A.","family":"Adekunle","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Tran","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Criswell","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ye","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Welch","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Yue","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"9","key":"zoi250541r1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"zoi250541r2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease.","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"zoi250541r3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"zoi250541r4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis.","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"zoi250541r5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States.","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"zoi250541r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019.","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi250541r7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"zoi250541r8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250541r11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.","volume":"72","author":"Loomba","year":"2023","journal-title":"Gut"},{"issue":"6","key":"zoi250541r12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"zoi250541r13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.18553\/jmcp.2023.29.10.1169","article-title":"Resmetirom for nonalcoholic steatohepatitis.","volume":"29","author":"Fahim","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"zoi250541r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050.","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250541r15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: a report of the ISPOR CHEERS II Good Practices Task Force.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"zoi250541r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies.","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi250541r17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/hep.21103","article-title":"Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.","volume":"43","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"issue":"9","key":"zoi250541r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.30426","article-title":"Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease.","volume":"5","author":"Chhatwal","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"17","key":"zoi250541r19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease.","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250541r20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/13696998.2022.2026702","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease.","volume":"25","author":"Rustgi","year":"2022","journal-title":"J Med Econ"},{"issue":"1","key":"zoi250541r22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hep4.1625","article-title":"The natural history of NAFLD, a community-based study at a large health care delivery system in the United States.","volume":"5","author":"Nyberg","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"zoi250541r23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"zoi250541r26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s41669-022-00370-2","article-title":"Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis.","volume":"7","author":"Javanbakht","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"zoi250541r28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cgh.2017.07.024","article-title":"Healthcare costs related to treatment of hepatocellular carcinoma among veterans with cirrhosis in the United States.","volume":"16","author":"Kaplan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"zoi250541r29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.","volume":"17","author":"McAdam-Marx","year":"2011","journal-title":"J Manag Care Pharm"},{"issue":"11","key":"zoi250541r30","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"zoi250541r31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"zoi250541r33","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.","volume":"49","author":"David","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"zoi250541r34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/02729890122062352","article-title":"Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36.","volume":"21","author":"Nichol","year":"2001","journal-title":"Med Decis Making"},{"issue":"3","key":"zoi250541r35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients.","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"zoi250541r36","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/lt.22388","article-title":"Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score.","volume":"17","author":"\u00c5berg","year":"2011","journal-title":"Liver Transpl"},{"issue":"4","key":"zoi250541r37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"2","key":"zoi250541r38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi250541r39","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"zoi250541r40","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"zoi250541r9","unstructured":"US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. March 14, 2024. Accessed February 20, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease"},{"key":"zoi250541r10","unstructured":"UpToDate Lexidrug. Resmetirom. Accessed December 9, 2024. https:\/\/online.lexi.com"},{"key":"zoi250541r21","unstructured":"National Center for Health Statistics, Centers for Disease Control and Prevention. Life tables. Accessed March 15, 2023. https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm"},{"key":"zoi250541r24","unstructured":"Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. Accessed March 20, 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html"},{"key":"zoi250541r25","unstructured":"Department of Health and Human Services, Health Resources and Services Administration. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2008-2015. Accessed May 31, 2019. https:\/\/optn.transplant.hrsa.gov\/data\/view-data-reports\/national-data\/"},{"key":"zoi250541r27","unstructured":"Tice? JA, Suh? K, Fahim? SM, . Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis (NASH); Draft Evidence Report. Institute for Clinical and Economic Review. April 2023. Accessed April 26, 2024. https:\/\/icer.org\/assessment\/non-alcoholic-steatohepatitis-2023\/"},{"key":"zoi250541r32","unstructured":"Ippolito BN, Levy JF. Estimating the cost of new treatments for diabetes and obesity. American Enterprise Institute. Accessed September 3, 2024. https:\/\/www.aei.org\/research-products\/report\/estimating-the-cost-of-new-treatments-for-diabetes-and-obesity\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835705\/le_2025_oi_250541_1750871462.69963.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:30:35Z","timestamp":1751023835000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17122","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}